- Home
- AVDL vs MGNI Comparison
AVDL vs MGNI Comparison
Compare AVDL & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- MGNI
- Stock Information
- Founded
- AVDL 2015
- MGNI 2007
- Country
- AVDL Ireland
- MGNI United States
- Employees
- AVDL N/A
- MGNI N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- MGNI Computer Software: Programming Data Processing
- Sector
- AVDL Health Care
- MGNI Technology
- Exchange
- AVDL Nasdaq
- MGNI Nasdaq
- Market Cap
- AVDL 1.4B
- MGNI 1.7B
- IPO Year
- AVDL 1996
- MGNI N/A
- Fundamental
- Price
- AVDL $11.66
- MGNI $17.13
- Analyst Decision
- AVDL Strong Buy
- MGNI Strong Buy
- Analyst Count
- AVDL 6
- MGNI 12
- Target Price
- AVDL $24.00
- MGNI $17.05
- AVG Volume (30 Days)
- AVDL 1.7M
- MGNI 2.4M
- Earning Date
- AVDL 11-12-2024
- MGNI 11-07-2024
- Dividend Yield
- AVDL N/A
- MGNI N/A
- EPS Growth
- AVDL N/A
- MGNI N/A
- EPS
- AVDL N/A
- MGNI 0.12
- Revenue
- AVDL $138,160,000.00
- MGNI $661,134,000.00
- Revenue This Year
- AVDL $533.23
- MGNI $0.39
- Revenue Next Year
- AVDL $73.08
- MGNI $10.90
- P/E Ratio
- AVDL N/A
- MGNI $144.00
- Revenue Growth
- AVDL 1523.50
- MGNI 8.71
- 52 Week Low
- AVDL $10.41
- MGNI $7.97
- 52 Week High
- AVDL $19.09
- MGNI $17.19
- Technical
- Relative Strength Index (RSI)
- AVDL 40.12
- MGNI 72.74
- Support Level
- AVDL $10.41
- MGNI $15.70
- Resistance Level
- AVDL $16.66
- MGNI $17.00
- Average True Range (ATR)
- AVDL 0.88
- MGNI 0.90
- MACD
- AVDL -0.31
- MGNI 0.22
- Stochastic Oscillator
- AVDL 20.00
- MGNI 98.92
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.